PMID- 1740540
OWN - NLM
STAT- MEDLINE
DCOM- 19920323
LR  - 20190824
IS  - 0091-2700 (Print)
IS  - 0091-2700 (Linking)
VI  - 32
IP  - 1
DP  - 1992 Jan
TI  - Evaluation of quinapril on regional blood flow and cardiac function in patients 
      with congestive heart failure.
PG  - 70-6
AB  - Quinapril, a nonsulfhydryl ACE inhibitor, was evaluated in ten New York Heart 
      Association (NYHA) functional class (FC) II-III CHF patients to determine its 
      effects on regional blood flow [effective renal plasma flow (ERPF), renal blood 
      flow (RBF), renal vascular resistance (RVR), hepatic blood flow (HBF), hepatic 
      vascular resistance (HVR), segmental limb pressure (SLP), creatinine clearance 
      (CRCL)] and cardiac function [left ventricular ejection fraction (LVEF)]. 
      Previous vasodilator therapy was withdrawn 2 weeks before baseline measurements. 
      Stable regimens of digoxin and diuretics were continued throughout the study. 
      ERPF was assessed using p-aminohippurate (PAH), HBF by indocyanine green (ICG) 
      clearance, and LVEF by radionuclide scintography. Segmental limb pressures were 
      measured by Doppler flow detection. Measurements were performed at baseline (B) 
      and after 4 weeks of quinapril therapy (10 mg BID). Quinapril increased renal (P 
      less than 0.05) and hepatic blood flow (P = 0.06) and significantly reduced renal 
      and hepatic vascular resistance. Glomerular filtration rate and left ventricular 
      ejection fraction were unchanged. Mean arterial pressure and brachial segmental 
      pressures decreased without change in heart rate. Noninvasive cardiovascular 
      assessments indicate that quinapril improves regional blood flow while exhibiting 
      no change in left ventricular ejection fraction, in patients with NYHA FC II-III 
      CHF.
FAU - Munger, M A
AU  - Munger MA
AD  - Division of Cardiology, University Hospitals of Cleveland, Case Western Reserve 
      University School of Medicine, Ohio.
FAU - Chance, M
AU  - Chance M
FAU - Nair, R
AU  - Nair R
FAU - Prescott, A W
AU  - Prescott AW
FAU - Nara, A R
AU  - Nara AR
FAU - Simonson, M S
AU  - Simonson MS
FAU - Green, J A
AU  - Green JA
FAU - Posvar, E L
AU  - Posvar EL
LA  - eng
GR  - M01RR00080/RR/NCRR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - J Clin Pharmacol
JT  - Journal of clinical pharmacology
JID - 0366372
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Isoquinolines)
RN  - 0 (Tetrahydroisoquinolines)
RN  - RJ84Y44811 (Quinapril)
SB  - IM
MH  - Antihypertensive Agents/administration & dosage/*pharmacology
MH  - Blood Pressure/drug effects
MH  - Female
MH  - Glomerular Filtration Rate/drug effects
MH  - Heart Failure/drug therapy/*physiopathology
MH  - Hemodynamics/*drug effects/physiology
MH  - Humans
MH  - Isoquinolines/administration & dosage/*pharmacology
MH  - Liver Circulation/drug effects
MH  - Male
MH  - Quinapril
MH  - Regional Blood Flow/drug effects
MH  - Renal Circulation/drug effects
MH  - Stroke Volume/drug effects
MH  - *Tetrahydroisoquinolines
MH  - Ventricular Function, Left/drug effects
EDAT- 1992/01/01 00:00
MHDA- 1992/01/01 00:01
CRDT- 1992/01/01 00:00
PHST- 1992/01/01 00:00 [pubmed]
PHST- 1992/01/01 00:01 [medline]
PHST- 1992/01/01 00:00 [entrez]
AID - 10.1002/j.1552-4604.1992.tb03791.x [doi]
PST - ppublish
SO  - J Clin Pharmacol. 1992 Jan;32(1):70-6. doi: 10.1002/j.1552-4604.1992.tb03791.x.